A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
- NCT00148486
- PHASE2
- INTERVENTIONAL
Last updated: 2013-10-29
Purpose of Trial
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
This study is for people with
Parkinson Disease
Interventions being studied
NS 2330
Parkinson's disease for \<5 years, non-demented, no or \<6 months of levodopa and none during trial. Off levodopa, DA agonists, and psychotropics for 30 days before screening. Amantadine, anticholinergics allowed if at stable dosage. Hoehn \& Yahr stage I-III. Depression allowed, but no other chronic disease that is unstable or might interfere with ability to participate.
ELIGIBILITY
Gender: ALL
Age: 40+
Healthy Volunteers: No
47 Locations
Peoria
Pivotal Reaserch Centers
Arizona, United States
Tucson
Boehringer Ingelheim Investigational Site
Arizona, United States
Fountain Valley
PMDI
California, United States
Fresno
Boehringer Ingelheim Investigational Site
California, United States
Irvine
Boehringer Ingelheim Investigational Site
California, United States
Ocenside
Boehringer Ingelheim Investigational Site
California, United States
Oxnard
Boehringer Ingelheim Investigational Site
California, United States
West Los Angeles
West Los Angeles VA Medical Center
California, United States
Danbury
Boehringer Ingelheim Investigational Site
Connecticut, United States
Farmington
UCONN Health Center
Connecticut, United States
New Haven
60 Temple St
Connecticut, United States
Boca Raton
Boehringer Ingelheim Investigational Site
Florida, United States
Bradenton
Boehringer Ingelheim Investigational Site
Florida, United States
Gainsville
University of Florida
Florida, United States
Hollywood
Sunrise Clinical Research
Florida, United States
Miami
Department of Neurology
Florida, United States
Miami
Miami Research Associates
Florida, United States
Ocala
Boehringer Ingelheim Investigational Site
Florida, United States
Ocala
Renstar Medical Research
Florida, United States
Panama City
Boehringer Ingelheim Investigational Site
Florida, United States
St. Piresburg
CNS Clinical Trials
Florida, United States
Tampa
Movement Disorder Center
Florida, United States
Tampa
University of Southern Florida
Florida, United States
Chicago
Department of Neurological Sciences
Illinois, United States
Fort Wayne
Boehringer Ingelheim Investigational Site
Indiana, United States
Indianapolis
Outpatient Clinical Research Facility
Indiana, United States
Kansas City
Boehringer Ingelheim Investigational Site
Kansas, United States
Shreveport
Boehringer Ingelheim Investigational Site
Louisiana, United States
Scarborough
Boehringer Ingelheim Investigational Site
Maine, United States
Springfield
Boehringer Ingelheim Investigational Site
Massachusetts, United States
Springfield
Future Care Studies
Massachusetts, United States
Traverse City
Boehringer Ingelheim Investigational Site
Michigan, United States
Minneapolis
Boehringer Ingelheim Investigational Site
Minnesota, United States
Minneapolis
University of Minesota
Minnesota, United States
Omaha
Boehringer Ingelheim Investigational Site
Nebraska, United States
Omaha
University of Nebraska Medical Center
Nebraska, United States
Toms River
Global Medical Institutes LLC
New Jersey, United States
Albany
Upstate Clinical Resaerch LLC
New York, United States
New York
Boehringer Ingelheim Investigational Site
New York, United States
Wiston-Salem
Boehringer Ingelheim Investigational Site
North Carolina, United States
Columbus
Ohio State University Medical Center
Ohio, United States
Dayton
Neurology Specialists Inc.
Ohio, United States
Tulsa
St. John's Doctor Building
Oklahoma, United States
Pittsburgh
University of Pittsburgh Medical Center
Pennsylvania, United States
Houston
The Methodist Hospital
Texas, United States
San Antonio
Boehringer Ingelheim Investigational Site
Texas, United States
Wichita Falls
North Texas Neurology Associates
Texas, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov
